AstraZeneca is working on an indication extension of ticagrelor for the prevention of cardiovascular (CV) death, myocardial infarction (MI) or stroke in patients with coronary arterial disease (CAD), but without medical history of previous MI or stroke at high risk of atherothrombotic events due to type II diabetes mellitus (T2DM). The ATHENA-F study purpose is to assess the prevalence and burden of CAD-T2DM without prior MI or stroke in France, as well as of the population with inclusion and exclusion criteria of the THEMIS randomized controlled trial (THEMIS-like population), using the French nationwide claims database (SNDS). The first study population will include all T2DM patients identified in 2013-2014 with CAD but without MI or stroke history, and affiliated to the general scheme from 2008 to 2016 (data extraction period). Each patient will be followed 2 years or until death and will have 5-year history in the database. THEMIS-like population will include patients of this first population aged ≥50 years at index, without history of intracranial bleeding, renal failure requiring dialysis, cirrhosis of liver or liver cancer, gastro-intestinal bleeding (within 6 months), antiplatelet agent or anticoagulant treatment within 2 months around index date. For prevalent patients (both T2DM and CAD), index date will be 01/01/2013, for incident patients the first date of the second diagnosis between T2DM or CAD. The number of CAD-T2DM patients is estimated to 550,000 patients in the SNDS, and the prevalence of the two study populations will be assessed on 01/01/2013 and 31/12/2014. The CV events (stroke, MI, CV death, all-cause death, heart failure, bleeding, and composite CV events of MI, stroke, CV death) during the study period will be described in terms of crude incidence rate (Normal approximation), cumulative incidence rate (Kaplan-Meier estimator or Cumulative Incidence Function), and risk factors of the composite CV events (Cox proportional hazards model).